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Abstract
The CDC7 kinase is essential for the activation of DNA replication
origins and has been implicated in the replication stress response.
Using a highly specific chemical inhibitor and a chemical genetic
approach, we now show that CDC7 activity is required to coordi-
nate multiple MRE11-dependent processes occurring at replication
forks, independently from its role in origin firing. CDC7 localizes at
replication forks and, similarly to MRE11, mediates active slowing
of fork progression upon mild topoisomerase inhibition. Both
proteins are also retained on stalled forks, where they promote
fork processing and restart. Moreover, MRE11 phosphorylation and
localization at replication factories are progressively lost upon
CDC7 inhibition. Finally, CDC7 activity at reversed forks is required
for their pathological MRE11-dependent degradation in BRCA2-
deficient cells. Thus, upon replication interference CDC7 is a key
regulator of fork progression, processing and integrity. These
results highlight a dual role for CDC7 in replication, modulating
both initiation and elongation steps of DNA synthesis, and identify
a key intervention point for anticancer therapies exploiting repli-
cation interference.
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Introduction
In eukaryotic cells, DNA replication initiates from multiple origins
[1,2]. CDC7 kinase is required for the firing of replication origins, by
phosphorylating multiple subunits of the MCM2–7 helicase complex
[3–5], thus initiating bidirectional replication [6,7]. In addition,
CDC7 kinase has important and yet poorly characterized roles in the
replication stress response. For instance, in human cells CDC7-
dependent phosphorylation of the mediator protein CLASPIN is
important for full activation of CHK1 by ATR and for maintaining
cell viability in the presence of drugs that affect replication fork
progression [8–11]. More recently, CDC7 has been shown to play a
role in processing stalled replication forks by promoting limited
resection that may be important for efficient replication fork restart
and possibly by controlling EXO1 nuclease [12]. Furthermore, the
dephosphorylation of the MCM complex—which is mediated by
protein phosphatase 1 and RIF1, counteracting CDC7—has been
associated with loss of replisome stability in Xenopus and human
cells [13]. RIF1/PP1 also protects stalled forks from DNA2-depen-
dent degradation [13–15].
The idea that CDC7 may contribute to the regulation of nucleases
is supported by work in budding yeast where CDC7 directly controls
the activation of the Mus81 nuclease in mitosis by direct phosphory-
lation of the Mms4 subunit of the Mus81–Mms4 complex, thus
promoting the disentanglement of DNA joint molecules [16].
Furthermore, several laboratories have elucidated the role of yeast
CDC7 kinase in controlling the formation of DNA double-strand
breaks (DSBs) during meiotic DNA replication to promote meiotic
recombination [17–22]. However, whether CDC7 plays a direct role
at forks and how it contributes to the control of replication fork
processing are largely elusive.
Many CDC7 inhibitors have been developed as potential anti-
cancer agents; among these, PHA-767491 and XL413 have become
tool compounds that have also been widely used to test CDC7 func-
tions. Direct comparison of these two compounds in biochemical
assays showed that XL413 is more specific than PHA-767491 [23].
In order to better elucidate CDC7 functions, we have recently gener-
ated and characterized an engineered cell line, based on the princi-
ple of the analogue-sensitive kinase [24], in which CDC7 activity
can be partially but very specifically reduced using a bulky ATP
competitor, 3MB-PP1. Importantly, all the phenotypes observed by
treating WT cells with 10 lM XL413 are recapitulated by treatment
with 10 lM 3MB-PP1 in this AS-CDC7 cell line, including reduction
of MCM2 phosphorylation at CDC7-dependent sites and a mild delay
in progressing through S-phase [25].
Drugs that target DNA replication fork progression such as
hydroxyurea (HU), DNA polymerases and DNA topoisomerase inhi-
bitors, and DNA-damaging compounds slow down forks causing
their reversal into a four-branched structure that can be detected by
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electron microscopy, also described as chicken-foot structure
[26–29]. Formation of these structures is promoted by several enzy-
matic activities, leading to BRCA1- and BRCA2-dependent deposi-
tion of a RAD51 filament on the regressed arm of the fork (reviewed
in [28,29]).
Fork reversal also occurs at endogenous obstacles in the absence
of genotoxic drugs and can be triggered by oncogene activation
[30,31]. It was thus proposed that the overall speed of each individ-
ual fork is determined by the combination of processive DNA
synthesis, pausing into a chicken-foot conformation and subsequent
restart [28].
Once regressed arms are formed, they are stabilized by BRCA2-
dependent assembly of RAD51 filaments on their ssDNA portion,
thus preventing nucleolytic attack and extensive fork degradation
that is mediated by either CTIP, MRE11 or EXO1 (reviewed in
[32,33]).
Lack of reversed fork protection in BRCA2-deficient cells leads to
a high level of genome instability and in particular to chromosomal
breakage, as well as sensitivity to various chemotherapeutic drugs
[34,35]. Thus, in genetic backgrounds with compromised fork
stability, reversed forks represent crucial entry points for processing
events that mediate chemosensitivity.
In this work, using the specific inhibitor XL413 and the AS-CDC7
cell line, we describe the role of the CDC7 kinase in the dynamics of
established replication forks. We find that CDC7 kinase promotes
MRE11-dependent processing of reversed replication forks and, by
doing so, contributes to the modulation of replication fork speed
and to chromosomal instability upon fork stalling, which is a hall-
mark of BRCA2-deficient cells.
Results
CDC7 promotes replication fork processing and collapse in HU
CDC7 kinase is known to be involved in DNA replication initiation
and checkpoint signalling [8,9,36–39]. To further characterize
CDC7-dependent events in the replication stress response, we
treated U2OS osteosarcoma-derived cancer cells and MCF10A
breast-derived immortalized cells with HU in the presence or
absence of the CDC7 inhibitor XL413. With both cell lines, we
observed that HU-induced phosphorylation of RPA2—the middle
subunit of the ssDNA-binding protein RPA—was greatly reduced, as
assessed by either altered electrophoretic mobility or specific anti-
phosphopeptide antibodies. In a time-course experiment, the
suppression of RPA phosphorylation in CDC7i-treated cells was
observed as early as 2 h post-treatment and throughout the course
of the experiment (Fig 1A). Intriguingly, the phosphorylation of
H2AX at serine 139 (cH2AX) that occurs upon fork stalling and is
further amplified upon fork collapse and formation of DNA double-
strand breaks (DSBs) [40] was also partially suppressed in XL413-
treated U2OS (Fig 1A). Similar results were obtained with breast-
derived immortalized MCF10A cells (Fig EV1A). In order to confirm
that the suppression of RPA2 and H2AX phosphorylation in
response to HU was specifically due to CDC7 kinase inhibition, we
used an analogue-sensitive CDC7 cell line in which the activity of
the kinase can be partially downregulated with the bulky ATP
competitive inhibitor 3MB-PP1 [25]. Treatment of AS-CDC7 cells
with 3MB-PP1 reduced both RPA2 and H2AX phosphorylation
occurring in HU-treated cells to a similar extent as XL413 in the
isogenic MCF10A cells (Fig EV1A and B), suggesting that when
CDC7 is inhibited, fewer DNA DSBs are generated and/or stalled
forks are differently processed.
To directly assess if CDC7 promotes formation of DNA DSBs
from stalled forks, we then performed neutral comet assays on
U2OS cells. Following exposure of cells to HU for 24 h with or with-
out XL413, we observed that CDC7 inhibition significantly reduced
the tail moment, which is proportional to the number of DNA DSBs
in the cell (Fig 1B). The formation of DNA DSBs in HU was also
suppressed when CDC7 was inhibited with 3MB-PP1 in the AS-
CDC7 cell line (Fig EV1C).
As DNA DSBs in HU can arise from replication fork collapse,
which is actively prevented by ATR signalling [41,42], we tested the
effects of CDC7i in the presence of the ATR inhibitor AZD6738
finding that the addition of XL413 strongly decreased RPA2 and
H2AX hyper-phosphorylation (Fig 1C).
In all previous experiments, the CDC7 inhibitor was added
30 min before HU, as we had previously shown that CDC7 inhibi-
tion can only delay the onset of checkpoint signalling (i.e. CHK1
phosphorylation) before it is established [8]. Consistent with these
early findings, we found that unlike a short pre-treatment with the
CDC7i, simultaneous cotreatment of cells with CDC7i and HU was
unable to prevent the phosphorylation of neither RPA2 nor H2AX
(Fig 1D).
These observations suggest that CDC7 activity is required for
replication fork processing or collapse upon sustained fork arrest,
particularly in the absence of proper checkpoint signalling.
However, as CDC7 is also required for origin firing, they may also
reflect fewer active forks present at the moment of HU addition in
cells cotreated with CDC7i, thus limiting fork-associated phosphory-
lation events.
CDC7 drives H2AX phosphorylation in HU independently from
origin firing and in a MRE11-dependent manner
In order to possibly uncouple CDC7 function in initiation and at
elongating forks, we first performed a titration from 0.123 to 10 lM
of the CDC7 inhibitor XL413 in U2OS cells and accurately measured
by flow cytometry the amount of DNA synthesis occurring at dif-
ferent doses as well as the amount of H2AX phosphorylation when
CDC7i-treated cells were also challenged with HU. This analysis
indicated that very low levels of CDC7i had almost no effects on the
rate of EdU incorporation which decreased then in a dose-dependent
manner at higher concentrations. Conversely, already at the lowest
concentration of XL413, we detected a profound reduction on HU-
induced H2AX phosphorylation. These data suggest a different level
of requirement for CDC7 activity in promoting efficient DNA synthe-
sis and in driving HU-dependent H2AX phosphorylation and suggest
that key targets of CDC7 activity in initiation and at forks may be
different or differently regulated (Fig EV2).
If CDC7 is indeed required to promote fork collapse indepen-
dently from its role in initiation, we reasoned that allowing cells to
enter S-phase and be held in HU in the presence of CDC7i would
allow the following events to occur: (i) the arrest of existing forks;
(ii) checkpoint activation, which would prevent further origin firing
and further loading of the initiator factor CDC45, as well as
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checkpoint-dependent contribution in protecting existing forks from
collapse; and (iii) further fork stabilization caused by CDC7 inhibi-
tion. Under these conditions, the subsequent removal of the CDC7i
would possibly cause fork destabilization, while keeping strong
checkpoint signalling and HU-mediated prevention of further initia-
tion events. Conversely, checkpoint inhibition would simultane-
ously cause both fork collapse and origin activation.
To test these hypotheses, U2OS cells were treated with XL413
and HU for 24 h; then, still in the presence of HU, XL413 was either
kept or washed off and cells incubated for a further 2 h (Fig 2A). As
a control for the checkpoint-dependent suppression of both origin
firing and replication fork stabilization, the ATRi AZD6738 was
included. Proteins were then analysed by Western blotting (Fig 2B)
and the levels of H2AX phosphorylation quantitatively assessed by
A B
C D
Figure 1. CDC7 inhibition suppresses histone H2AX and RPA2 phosphorylation and DNA double-strand break formation upon fork stalling.
A U2OS cells were either mock-treated or treated with 10 lM XL413 for 30 min, at which point 4 mM HU was added and cells further incubated for the indicated
times. Whole-cell extracts were then analysed by Western blotting with the indicated antibodies. Reduction of phosphorylation of Ser40/41 on MCM2 is indicative of
CDC7 inhibition by XL413. Data are representative of two independent experiments.
B U2OS cells were either mock-treated or treated with 10 lM XL413, 4 mM HU or both for 24 h before performing neutral comet assays. Representative images of
comets are shown. Scale bar = 100 lm. In the dot plots, ~800 comets per each condition were analysed, means are indicated with a red line, and their values are
shown above the plot. Data are from two independent experiments.
C U2OS cells were either untreated or treated with 10 lM XL413 or with 5 lM AZD6738 alone or in combination and, where indicated, after 30 min, 4 mM HU was
added for a further 2 h. Whole-cell extracts were analysed by Western blotting with the indicated antibodies. Total protein stain (TPS) is as a loading control. Data
are representative of two independent experiments.
D U2OS cells were either untreated or treated with 4 mM HU for 5 h in the presence or absence of 10 lM XL413, which had been added to cells either 30 min prior to
(pre-treatment) or during (cotreatment) the addition of HU. Whole-cell extracts were analysed by Western blotting with the indicated antibodies, and total protein
stain (TPS) is displayed as a loading control. Data are representative of two independent experiments.
Source data are available online for this figure.
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flow cytometry (Fig 2C). In this assay, treatment with HU and
XL413 for 24–26 h arrested cells in S-phase with active checkpoint
and low levels of cH2AX (Fig 2B, lanes 4 and 6; and Fig 2D).
However, removal of CDC7i after 24 h clearly caused 2 h later a
marked increase in cH2AX and CHK1 phosphorylation (Fig 2B,
lanes 4 and 5; and Fig 2D). Importantly, this was not accompanied
by an increase in chromatin-bound CDC45, which is a surrogate
marker for origin firing. Conversely, CDC45 was clearly and expect-
edly increased upon treatment with the ATRi AZD6738 and occurred
in the absence of detectable EdU incorporation (Appendix Fig S1).
Fork collapse and DSB formation are thought to be due to the
loss of protection from the attack of several active nucleases, includ-
ing MRE11 and EXO1. While EXO1 levels were previously reported
to be downregulated by a promiscuous CDC7 inhibitor, PHA-767491
[12], these were not affected by XL413 (Appendix Fig S2). We there-
fore tested MRE11 involvement in H2AX phosphorylation after the
removal of CDC7 inhibition in HU. Indeed, MRE11 inhibition by
mirin [43] strongly limited histone H2AX and CHK1 phosphoryla-
tion to almost similar levels as maintaining the CDC7 inhibition
(Fig 2B, lanes 5–7; and Fig 2D).
Altogether, these experiments strongly support the notion that
CDC7 activity promotes MRE11-dependent processing of stalled
replication forks, independently from its role in regulating origin fir-
ing (Fig 2E), which can lead to checkpoint signalling amplification.
CDC7 and MRE11 associate with nascent DNA, and CDC7 is
required for maintenance of MRE11 localization at
replication factories
To further corroborate the hypothesis that CDC7 and MRE11 may
act directly at replication forks, we performed a series of experi-
ments to assess whether these proteins could be specifically
captured on nascent DNA by DNA-mediated chromatin pull-down
(Dm-ChP), a technique which is very similar to iPOND [44,45].
Firstly, in a pulse chase experiment we observed that the two
proteins could be efficiently cross-linked to newly synthesized DNA,
while their levels were substantially reduced on mature chromatin
(Fig 3A), which is also consistent with previous studies coupled to
mass spectrometry [45,46]. Both proteins could be still detected at
replication forks when their progression was arrested by HU up to
24 h, but CDC7 inhibition notably reduced their retention at forks
(Fig 3B and C).
During the course of these experiments, we noticed that after a
prolonged arrest in HU, a small fraction of MRE11 protein, which
was also captured on stalled forks, was retarded in its elec-
trophoretic mobility, and that its abundance was markedly
decreased upon CDC7 inhibition (Fig 3C). Subsequently, we found
that MRE11 altered electrophoretic mobility was sensitive to the
method of protein extraction and that a mild treatment of cells with
PFA before lysis greatly helped in its detection. We reasoned that
this could be due to a post-translational modification, most likely
due to phosphorylation, which could be easily lost in native
extracts. To test this hypothesis, new extracts were prepared from
U2OS cells that had been either mock-treated or treated with HU.
Again, a slower migrating form of MRE11 was detected in HU-
treated cells, which was decreased by cotreatment with XL413.
Importantly, MRE11 electrophoretic mobility shift was completely
lost upon incubation of these extracts with purified lambda
phosphatase (Fig 3D). Altogether, these experiments suggest that
CDC7 may control MRE11 by regulating its phosphorylation status.
In order to refine our analysis, we assessed MRE11 localization
by immunofluorescence microscopy. In these experiments, after
drug treatments and fixation, cells were stained with anti-MRE11
and anti-PCNA antibodies. As previously described, MRE11 can be
detected in a large number of nuclear foci and in HU-arrested cells
with a high degree of colocalization with PCNA, indicative of its
association with replication factories [35,47]. Treatment with the
CDC7 inhibitor markedly reduced the degree of colocalization of the
two proteins (Fig 3E and F). Partial colocalization of MRE11 with
RPA2 was also reduced by CDC7 inhibition, albeit to a lesser extent
(Fig EV3).
We conclude that both CDC7 and MRE11 associate with nascent
DNA and are retained at forks upon prolonged HU stalling.
However, a discrete pool of MRE11 protein requires CDC7 activity
to retain its localization at replication forks, possibly because of
CDC7 control of MRE11 phosphorylation status.
CDC7 contributes to fork restart and determines fork speed
In order to evaluate the role of CDC7 at paused forks, before their
collapse, we measured the efficiency of fork restart after a transient
HU arrest. In a first set of experiments using MCF10A cells, ongoing
forks were marked with IdU in the presence or absence of CDC7i,
cells were then treated with HU for 2 h, after which DNA synthesis
was allowed to resume by removing HU and new DNA synthesis
was labelled with CldU. Notably, CDC7 inhibition markedly
increased the fraction of forks that were unable to restart within the
time frame of the experiment (Fig 4A). These results suggest that a
CDC7-dependent event is specifically required for efficient resump-
tion of temporary arrested replication forks, and remind of a similar
deficiency in fork restart described upon depletion of the MRE11
nuclease [48], which we confirmed in U2OS cells upon MRE11 inhi-
bition with mirin (Fig 4B). The addition of CDC7i did not signifi-
cantly exacerbate the fork restart defect induced by mirin (Fig 4B),
suggesting that CDC7 and MRE11 are working at a common func-
tion in fork restart.
We then asked if CDC7 activity was also required upon treat-
ments that slow down but do not terminally arrest forks. Low levels
of camptothecin (CPT), a topoisomerase I inhibitor, have been
shown to induce a large number of reversed forks and substantially
reduce replication fork speed in the absence of detectable chromoso-
mal breakage [27]. As fork slowdown under these conditions was
shown to genetically depend on fork reversal activities [26,49], it
was suggested that CPT induces fork slowing by increasing topologi-
cal stress and transiently pausing DNA synthesis at forks converted
in a chicken-foot conformation. Using DNA fibre assay, we therefore
assessed the effect of CDC7 and MRE11 inhibition in combination
with low levels of CPT. In these experiments, replication intermedi-
ates were first labelled with CldU, and then, 50 nM CPT was added
together with IdU; the change in the velocity of the forks during
drug treatment was measured as the ratio between CldU- and IdU-
containing tracks in the same DNA fibre (Fig 4C). As previously
shown, CPT treatment drastically reduced the length of the DNA
molecules synthesized during the second labelling period, consistent
with reduced fork speed. Remarkably, when XL413 was added prior
to CPT, IdU-labelled tracks were of similar length to those observed
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Figure 2. CDC7 inhibition suppresses histone H2AX phosphorylation independently from origin firing.
A Outline of experimental procedure. U2OS cells were either untreated or treated with 10 lM XL413 or with 4 mM HU in the presence or absence of XL413 for 24 h.
Cells were EdU-labelled for 30 min before harvesting. Cells that had been treated with both XL413 and HU for 24 h were washed with equilibrated media and
retreated for a further 2 h. All further treatments included 4 mM HU, to prevent further DNA synthesis in either the absence or presence of CDC7 (XL413), MRE11
(Mirin) or ATR (AZD6738) inhibitors.
B CSK soluble and chromatin-enriched protein fractions were analysed by Western blotting with the indicated antibodies. Data are representative of two
independent experiments.
C, D Flow cytometry analysis to assess the levels of pS139 histone H2AX (c). Histograms show the mono-parametric analysis of cell count against pS139 histone H2AX
intensity. Histograms are overlaid to appreciate changes in pS139 histone H2AX intensity upon treatment (red lines) relative to appropriate experimental baseline
controls (grey lines). Data are representative of two independent experiments.
E Graphical concept: cells treated with HU and XL413 for 24 h would have stalled forks, which exist in a stable state due to inhibition of CDC7 and with an active
ATR-dependent origin firing checkpoint. Upon washing and retreating of cells in the presence of HU, the late origin checkpoint is maintained, in an ATR-dependent
manner, and accumulation of DNA damage (pS139 H2AX) can be monitored independently from origin firing in the absence or presence of CDC7 (XL413) or MRE11
(Mirin) inhibitor. AZD6738 was used as a control to investigate molecular events occurring upon loss of checkpoint caused by both fork collapse and loss of the
inhibition of origin firing. The increase in chromatin binding of CDC45 was used as a surrogate marker for origin (ori) activation, pS139 histone H2AX was used to
monitor fork stability, pS345 CHK1 was used to monitor the ATR-checkpoint signalling, and pS40/41 MCM2 was used to monitor CDC7 kinase activity.
Source data are available online for this figure.
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in mock-treated cells. Strikingly, the addition of mirin (Fig 4C) or
MRE11 depletion (Fig 4D) was also sufficient to allow unrestrained
fork progression in the presence of CPT. The combination of XL413
with mirin or MRE11 depletion did not result in further enhance-
ment of fork speed compared to XL413 alone (Fig 4C and D).
Altogether, these results indicate that CDC7 and MRE11 act
epistatically in the processing of replication forks facing a transient
arrest. As neither CDC7 nor MRE11 inhibition was shown to affect
damage-induced formation of reversed forks [50,51], these data also
strongly suggest that, in addition to fork remodelling, active slowing
of replication forks requires CDC7- and MRE11-dependent process-
ing of newly synthesized DNA.
CDC7 promotes the degradation of reversed forks
Previous studies have indicated that HU-arrested replication forks
undergo reversal [28]. Regressed arms at these remodelled forks are
coated by RAD51 filaments in a BRCA2-dependent manner and,
upon BRCA2 deficiency, are readily subjected to aberrant nucle-





Figure 3. CDC7 is a replisome-associated protein, and its inhibition affects the localization of MRE11 at replication factories.
A U2OS cells were labelled with EdU for 30 min; then, EdU was washed, and cells were further incubated for either 1 or 2 h in the presence of thymidine. At the
indicated time points, cells were fixed and proteins binding to EdU-labelled DNA captured by the DNA-mediated chromatin pull-down technique (DmChP). Graphical
experimental outline is shown above the analysis by Western blot of relevant proteins in both input and captured materials.
B U2OS cells were labelled with EdU for 30 min and then treated with 4 mM HU for 2 h in the presence or absence of 10 lM XL413. Proteins binding to EdU-labelled
DNA captured by DmChP were then analysed by Western blot as above.
C As in panel B, but incubation with HU was extended to 24 h. Black arrow indicates MRE11 electrophoretic mobility shift.
D U2OS cells were either mock-treated or treated with 10 lM XL413 for 30 min, at which point 4 mM HU was added and cells incubated for a further 24 h. Extracts
prepared from HU-treated cells were then incubated in the presence or absence of k-phosphatase. Proteins were analysed by Western blotting with anti-MRE11
antibodies. Total protein stain (TPS) is used as a loading control. Black arrow indicates MRE11 electrophoretic mobility shift.
E U2OS cells were treated with 4 mM HU in the presence or absence of 10 lM XL413 for 24 h. PCNA (green) and MRE11 (red) were detected by immunofluorescence.
Insets I–II represent enlargements of selected region of the merged images.
F Quantification of PCNA and MRE11 colocalization was assessed with ImageJ in ~70 randomly selected cells for each condition from four biological replicates and
expressed as Pearson’s correlation coefficient. Error bars represent SEM. Statistical significance was assessed by Student’s t-test (*P ˂ 0.05).
Source data are available online for this figure.
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Figure 4. CDC7 is required for efficient fork restart and, together with MRE11, regulates fork speed.
A MCF10A cells were either mock-treated or treated with 10 lM XL413 and labelled with IdU (red) for 30 min, at which point 4 mM HU was added for 2 h. HU was
then washed off and cells labelled with CldU (green) in the continued presence or absence of XL413. A set of representative DNA fibres from each condition is shown,
and the percentage of IdU (red)-only tracts is plotted. At least 200 replication forks were analysed for each condition. Error bars represent SEM from three biological
repeats, and statistical significance was assessed by the Student t-test (**P ˂ 0.01).
B U2OS cells were either mock-treated or treated with 10 lM XL413, 50 lM Mirin or both and labelled with IdU (red) for 30 min, at which point 4 mM HU was added
for 2 h. HU was then washed off and cells labelled with CldU (green) in the continued presence or absence of XL413 and/or Mirin. A set of representative DNA fibres
from each condition is shown, and the percentage of IdU (red)-only tracts is plotted. At least 200 replication forks were analysed for each condition. Error bars
represent SEM from four biological repeats, and statistical significance was assessed by the Student t-test (*P < 0.05, **P ˂ 0.01).
C U2OS cells were either mock-treated or pre-treated for the indicated times with 10 lM XL413, 50 lM Mirin or both and labelled with CldU (red). Then, 50 nM CPT
was added and cells labelled with of IdU (green) for a further 30 min. A set of representative DNA fibres from each condition is shown and the IdU/CldU tract length
ratio is plotted. The box extends from the 25th to the 75th percentile with the line in the box representing the median. Whiskers indicate the 10–90 percentiles with
data outside this range for individual outliers being plotted as dots. At least 100 replication forks were analysed for each condition. P-values were calculated using
one-way ANOVA, Kruskal–Wallis test and Dunn’s multiple comparison post-test (ns, not significant; ****P < 0.0001) and are related to the experiment shown. Similar
results were obtained in a second independent experiment.
D U2OS cells were transfected with control (siLuc) or MRE11-targeting siRNA (siMRE11). After 48 h, cells were either mock-treated or pre-treated with 10 lM XL413
and labelled with CldU (red) for 30 min. Where indicated, 50 nM CPT was added, and then, cells were labelled with IdU (green). A set of representative DNA fibres
from each condition is shown, and the IdU/CldU tract length ratio is plotted. The box extends from the 25th to the 75th percentile with the line in the box
representing the median. Whiskers indicate the 10–90 percentiles with data outside this range for individual outliers being plotted as dots. At least 100 replication
forks were analysed for each condition. P-values were calculated using one-way ANOVA, Kruskal–Wallis test and Dunn’s multiple comparison post-test (ns, not
significant; ****P < 0.0001) and are related to the experiment shown. Similar results were obtained in two other independent experiments.
Source data are available online for this figure.
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In order to monitor the effects of CDC7 inhibition on arrested
replication forks, we implemented a fork degradation assay based
on DNA fibre spreading. For this purpose, U2OS cells were labelled
with two consecutive 20-min pulses of nucleoside analogues (CldU
and IdU) and then treated with HU for 5 h in the presence or
absence of XL413 (Fig 5A). The degradation of arrested forks was
then assessed by calculating the ratio between the length of IdU-
over CldU-containing tracks in individual fibres. These experiments
were performed in cells transfected with control or BRCA2-targeting
siRNAs, with the goal to assess the impact of CDC7 inhibition on
fork protection mechanisms (Fig 5B). We observed that CDC7
inhibition had no obvious effect in U2OS cells transfected with
control siRNA and that, as expected, forks were degraded in
BRCA2-depleted cells. Notably, we found that the addition of the
CDC7 inhibitor together with HU fully protected replication forks
from degradation (Fig 5C and D).
In principle, the rescue from degradation by CDC7i in BRCA2-
deficient cells could be consistent with defective formation of
reversed forks—i.e. the entry point for fork degradation—or with
induced protection of reversed forks from nuclease digestion
despite the BRCA2 defect. To discriminate among these possibili-
ties, we used electron microscopy (EM) to directly analyse the
replication intermediates that accumulate in HU-treated cells
(Fig 5E). When specifically assessing the percentage of detectable
reversed forks in the different samples, we found that in wild-type
cells, the inclusion of the CDC7 inhibitor during the treatment with
HU did not significantly alter their frequency, in keeping with
previous evidence upon DNA-damaging agents [51]. As previously
shown [35,50,52–55], BRCA2 depletion causes the loss of reversed
fork structures in the sample. However, we strikingly found that
CDC7 inhibition completely rescues the decrease in reversed fork
frequency observed in BRCA2-depleted cells (Fig 5F and
Appendix Table S1). In agreement with the results obtained with
the DNA fibre assay, EM analysis also indicated that CDC7 inhibi-
tion abolishes the accumulation of extended ssDNA regions, which
are observed at stalled forks upon BRCA2 depletion (Fig 5G).
Furthermore, immunofluorescence microscopy analysis of HU-
treated BRCA2-depleted cells showed that CDC7 inhibition did not
rescue the focal recruitment of RAD51, indicating that in these
conditions, arrested forks are not protected by enforcing RAD51 fil-
ament formation (Appendix Fig S3), and further suggesting a role
for CDC7 in fork resection. We therefore conclude that CDC7
kinase does not affect the formation of reversed forks but promotes
their degradation when fork protection is lost.
CDC7 contributes to replication stress-induced
chromosomal breakages
As fork stalling is a main source of chromosomal damage and
genome instability (reviewed in [56]), we assessed the effects of
CDC7 inhibition on the integrity of mitotic chromosomes in WT and
BRCA2-depleted cells optionally treated with HU.
In a first set of experiments, U2OS cells and AS-CDC7 MCF10A
cells were incubated with HU for 5 h with DMSO as control or with
XL413 or 3MB-PP1, respectively, and then released into nocodazole
for 16 h, in order to complete DNA synthesis before arresting in
mitosis. Metaphase spreads were prepared, and chromosome integ-
rity was assessed by fluorescence microscopy (Fig 6A). HU
treatment greatly increased the average number of chromatid breaks
in both cell lines. However, when a CDC7 inhibitor was included in
the medium, the levels of chromosome breaks were dramatically
reduced, regardless of their BRCA2 status (Fig 6B and C).
Since in BRCA2-deficient cells chromatid breaks arise at higher
frequency even without HU—possibly as a consequence of the loss
of protection of forks stalling at endogenous obstacles and MRE11-
dependent degradation [34]—we tested whether CDC7 also contri-
butes to spontaneous chromosome aberrations. U2OS or AS-CDC7
cells were transfected with a control or BRCA2-targeting siRNAs and
then either mock-treated or treated for 24 h with XL413 or 3MB-
PP1, respectively, before metaphase spread analysis. Notably,
partial inhibition of CDC7 strongly reduced chromosome damage
also in untreated BRCA2-depleted cells (Fig 6D and E).
Although it is possible that the effect of CDC7 inhibition on
decreasing chromosome breaks might be in part mediated by a
reduction in the number of active forks, these results are also
consistent with the idea that, in the absence of fork protection,
CDC7 kinase promotes MRE11 nuclease attack of reversed forks
leading to chromosomal instability.
Discussion
The duplication of human genomic DNA poses numerous threats to
genome integrity, as a large quantity of DNA needs to be rapidly
synthesized, containing endogenous obstacles to replication fork
progression. This task is achieved through the robust and tempo-
rally regulated activation of numerous origins of replication and by
modulation of the speed of replication forks which temporarily
pause and restart. Furthermore, several safeguard mechanisms
evolved to protect fork integrity, repair DNA lesions arising at forks
and modulate further origin activation.
CDC7 kinase and CDKs are the two master S-phase-promoting
factors that control origin activation. It is well established that CDKs
regulate origin firing with CDK-dependent phosphorylation events
regulating origin licensing and usage (reviewed in [57,58]). At the
same time, CDKs control the activity of enzymes required for deal-
ing with replication stress, including the CtIP and EXO1 nucleases
and the MRN complex [59,60].
In this work, we demonstrate that CDC7 kinase behaves similarly
to CDKs, with the dual function of promoting origin firing and
contributing to the processing of paused forks, leading to efficient
restart and effective DNA synthesis. Our phenotypical analysis
strongly points to the possibility that the primary target of CDC7
regulation in fork processing is the MRE11 nuclease. CDC7 inhibi-
tion mirrors many phenotypes that have been ascribed to MRE11
inhibition, strongly indicating that these two proteins act together,
at both unchallenged and stalled forks.
MRE11 processing is important for fork restart, but uncontrolled
nuclease activity can be extremely detrimental and multiple mecha-
nisms exist to restrict MRE11 activity (reviewed in [61]). At paused
replication forks, this is achieved through RAD51- and
BRCA2-dependent protection, preventing pathological degradation
of nascent DNA starting from reversed forks [35,50,52–55,62]. As
CDC7 inhibition does not affect the formation of reversed forks [51],
nor focal recruitment of RAD51, the rescue of fork stability by
CDC7i in BRCA2-deficient cells is most likely due to absence of
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Figure 5. CDC7 promotes the nucleolytic degradation of reversed forks in BRCA2-deficient cells.
A U2OS cells were transfected with control (siLuc) or BRCA2-targeting siRNA (siBRCA2). After 48 h, cells were either mock-treated or treated with 10 lM XL413 for
30 min and labelled consecutively with CldU (red) and IdU (green), followed by treatment with 4 mM HU for a further 5 h.
B Representative Western blot of indicated proteins obtained from whole-cell extracts. pS40/41 on MCM2 indicates effective CDC7 inhibition by XL413.
C The ratios of IdU/CldU tract length are plotted. The box extends from the 25th to the 75th percentile with the line in the box representing the median. Whiskers
indicate the 10–90 percentiles with data outside this range for individual outliers being plotted as dots. Mean values of IdU/CldU ratios are indicated above the plot.
At least 100 replication forks were analysed for each condition.
D The mean values of IdU/CldU tract length ratios from three independent experiments are plotted, with the standard deviation (blue lines) and mean (red line).
Statistical analysis: Student’s t-test; ns, not significant; **P < 0.01; ***P < 0.001
E Electron micrographs of representative replication forks from U2OS cells: A reversed fork is labelled: P = parental strand; D = daughter strand; and R = regressed
arm; the four-way junction at the reversed fork is magnified in the inset. The red arrows indicate single-stranded DNA at the fork. Scale bar is 200 nm (= 460 bp)
and 100 nm (= 230 bp) in the inset.
F Frequency of reversed replication forks isolated from mock-depleted (siLuc) and BRCA2-depleted (siBRCA2) U2OS cells upon 5-h treatment with 4 mM HU in the
presence or absence of 10 lM XL413. The number of replication intermediates analysed is indicated in parentheses. Similar results were obtained in two independent
experiments (Appendix Table S1).
G Amount of ssDNA length at the junction (red arrows in Fig 4D) in siLuc and siBRCA2 U2OS cells treated with 4 mM of HU for 5 h in the presence or absence of XL413.
N indicates the number of forks observed, and only molecules with detectable ssDNA stretches are included in the analysis. The lines show the mean length of ssDNA
regions at the fork, and the value is displayed above the plot.
Source data are available online for this figure.
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pathological resection, consistent with CDC7 allowing MRE11 action
at unprotected reversed forks.
Unlike a previous report [12], in our experiments we did not
observe fork degradation occurring upon HU treatment in WT cells,
where fork protection is efficient, and therefore, we were unable to
measure the effects of CDC7i in this context. However, the fact that
CDC7 inhibition, also in WT cells, prevents the accumulation of
DNA DSBs in response to HU and limits chromatid breaks that origi-
nated from replication stress is a strong indication that fork protec-
tion can occasionally fail also in BRCA2-proficient cells, allowing
access of nucleases and leading to fork collapse. Fork collapse in
HU can be highly stimulated by deficiency in the ATR/CHK1 check-
point signalling [41,63]; remarkably, we and others find that such
excessive fork collapse in the presence of HU and checkpoint
inhibitors can be limited by both promiscuous and specific CDC7
inhibitors (Fig 1C) [12,63]. Although this effect of CDC7 inhibition
was previously attributed to reduced levels of origin firing and
thereby of active forks prone to collapse, we now propose that
CDC7 actively contributes to fork instability and DNA damage by
promoting the aberrant processing of unprotected forks by MRE11.
Of particular relevance is the new finding that both MRE11 and
CDC7 are required to slow down replication forks in response to
topological stress, indicating that whenever a fork pauses in a
chicken-foot conformation, DNA processing occurs and represents a
major determinant of the temporal delay in fork progression. Intrigu-
ingly, long treatments with CDC7 inhibitors have been reported to
increase fork speed in the presence of sub-limiting doses of HU [64]
or in the absence of other drugs [65,66]. In both cases, this was
A B D
C E
Figure 6. CDC7 contributes to replication-dependent chromosomal breakages.
U2OS or AS-CDC7 cells were transfected with control (siCon) or BRCA2 (siBRCA2)-targeting siRNAs and then either mock-treated or treated with 4 mM HU for 5 h in the
presence or absence of 10 lM XL413 or 3MB-PP1, respectively. HU was then washed off and nocodazole was added to the medium in order to complete one round of DNA
synthesis. Metaphase spreads were prepared and analysed.
A Representative metaphase spread from BRCA2-depleted U2OS cells treated with HU. Scale bar = 5 lm. Arrows indicate the chromosomes enlarged in the insets,
two of which show chromatid breaks (*).
B, C The graphs show the average number of chromatid breaks per spread. In each experiment, 30 chromosome spreads for each condition were analysed and three
independent experiments were performed. Error bars represent SEM. Statistical significance was assessed by Student’s t-test (**P ˂ 0.01, ***P < 0.001).
D, E U2OS and AS-CDC7 cells were transfected with control (siCon) or BRCA2 (siBRCA2)-targeting siRNAs. Forty-eight hours post-transfection, cells were either mock-
treated or treated with 10 lM XL413 or 10 lM 3MB-PP1, respectively, for 24 h with nocodazole added for the last 16 h of the experiment. The graph shows the
average number of chromatid breaks per spread. In each experiment, 30 chromosome spreads for each condition were analysed and three independent
experiments were performed. Error bars represent SEM. Statistical significance was assessed by Student’s t-test (*P < 0.05, ***P < 0.001).
Source data are available online for this figure.
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suggested to be caused by an ill-defined compensatory mechanism
that allows forks to accelerate when origin firing is limited, as it was
shown that forks emanating from distantly spaced origins tend to
move faster than those associated with short replicons [67]. We now
propose that besides its coordination with the number of active
forks, fork speed is directly modulated by the engagement of nucle-
olytic processing during transient fork pausing and reversal. Besides
fork reversal activities, this mechanism requires both CDC7 and
MRE11 and actively keeps the fork in an idle status, transiently
incompetent for DNA synthesis.
We further show that both the collapse and the pathological degra-
dation of unprotected reversed forks require active MRE11 and CDC7.
These deleterious effects on genome stability are likely to be the price
to pay in order to promote an efficient S-phase progression, which
requires regulated processing to efficiently restart forks that encounter
obstacles in their progression, such as tightly bound chromatin
proteins, difficult-to-replicate DNA structures or collisions with the
transcriptional machinery [29,68–70]. In that respect, it is not surpris-
ing that the S-phase-promoting kinase CDC7 may play a complex role
in initiation, elongation and efficient restart of DNA synthesis.
CDC7 has already been reported to influence MRE11 activity
through phosphorylation of the HSP90 chaperone, thus stabilizing a
ATR–HSP90–HCLK2–MRE11 complex [71]. Based on our data, it is
tempting to speculate that CDC7 may regulate MRE11-dependent
processes through direct phosphorylation, promoting MRE11 nuclease
activity and, in the long range, its retention at replication factories.
Such direct kinase substrate model will need further investigation, but
is already supported by the observation that fork-bound MRE11 in HU
displays a CDC7-dependent phosphorylation mobility shift. Further-
more, several of the reported MRE11 phosphorylation sites resemble
CDC7 preferred sites, which include S/T just before an acidic residue,
as well as S/TpSP sites. As CDC7 is largely cell cycle regulated and, as
we now show, is also a component of the replisome, such direct
mechanism provides an obvious way to regulate in time and space
MRE11 function at forks while restraining its activity outside S-phase.
However, our data do not exclude that other proteins may also be key
CDC7 targets at stalled forks. Among plausible candidates is the MCM
complex, which, in the absence of a robust CDC7 activity, readily
becomes dephosphorylated in a RIF1/PP1-dependent manner, corre-
lating with replisome instability and impaired capability of resuming
DNA synthesis after fork stalling [13]. Further studies will be required
to fully understand how CDC7 acts at forks, uncovering the effects of
specific CDC7-dependent phosphorylation events on given substrates
and at specific phosphorylation sites.
Finally, these results have strong implications on the use of CDC7
inhibitors in a clinical setting. This is particularly important when
considering CDC7 inhibitors in combination therapies with S-phase
genotoxic agents, which cause fork stalling and whose efficacy is
dependent on the amount of DNA damage that is produced upon fork
processing, in both BRCA2-deficient and BRCA2-proficient patients.
Materials and Methods
Cell culture
All cells were maintained at 37C with 5% CO2 in a humidified
atmosphere. U2OS (HTB-96; ATCC) cells were cultured in DMEM
supplemented with 10% (v/v) foetal bovine serum, 50 U/ml peni-
cillin and 50 lg/ml streptomycin. MCF10A (CRL-10317; ATCC) and
derivative cell lines were cultured in DMEM supplemented with 5%
(v/v) horse serum, 100 ng/ml cholera toxin, 10 lg/ml insulin,
20 ng/ml epidermal growth factor (Peprotech), 500 ng/ml hydro-
cortisone, 50 U/ml penicillin and 50 lg/ml streptomycin. MCF10A
cells expressing analogue-sensitive CDC7 (MCF10A AS-CDC7) were
generated as previously described [25].
Chemicals
Cell culture reagents and chemicals were obtained from Sigma-
Aldrich unless otherwise stated. Hydroxyurea (HU, H8627) and
camptothecin (CPT, C9911) were used at concentrations of 4 mM
and 50 nM, respectively. PHA-767491 (3140; TOCRIS Bioscience),
XL413 (synthesized in-house) and 3MB-PP1 (Cayman Chemical Co.,
17860) were all used at a concentration of 10 lM, while AZD6738
and mirin (HY-19323 and HY-19959; MedChemExpress) were
used at 5 and 50 lM, respectively. DMSO was used as a vehicle
control.
siRNA transfections
Transfections were performed according to the manufacturer’s
instructions. Cells were seeded in 6-well plates and, after 24 h, were
transfected with siRNA targeting either BRCA2 (UUGACUGAG
GCUUGCUCAGUUdTdT) [50], EXO1 (SI02665145; Qiagen) or siCon-
trol (GCAUAUCGUCGUAUACUAUdTdT) [25] at a final concentra-
tion of 75 nM using JetPrime reagent (related to Fig 6 and
Appendix Fig S2). Downregulation of MRE11 (Silencer Select,
4392420, IDs8961; Ambion) or BRCA2 (related to Figs 4 and 5,
respectively) was performed in 100-mm dishes over a 48 h period
using 40 nM final concentration of siRNA and RNAiMAX transfec-
tion reagent with siLuciferase as a control (CGUACGCGGAAUAC
UUCGAUUdTdT) [50].
Protein manipulations
Whole-cell extracts for BRCA2 (related to Fig 5) were prepared by
lysing cells in SDS buffer and resolved as previously described
[50]. Alternatively, cells were lysed in 1x Laemmli buffer for total
cell lysates or fractionated using CSK buffer supplemented with
protease and phosphatase inhibitors to obtain soluble and chro-
matin-enriched cell fractionations as previously described [72]. For
analysis of proteins that were associated with nascent DNA, cells
were plated at 9 × 106 cells/150 mm plate. Following treatments,
cells were processed and analysed using the DNA-mediated chro-
matin pull-down (Dm-ChP) technique as previously described [44].
The MRE11 phosphorylation shift was detected using a protocol
adapted from Dm-ChP sample preparation. Briefly, after the appro-
priate treatments in culture, cells were rapidly washed twice with
PBS and then incubated in media containing 1% PFA for 10 min at
room temperature with rocking (40 rpm) prior to quenching with
0.125 M glycine for a further 10 min. Cells were then washed three
times with ice-cold PBS, harvested by scrapping and pelleted by
centrifugation in microfuge tubes at 1,200 rpm for 5 min at 4°C.
Cell pellets were lysed in CL buffer (50 mM HEPES [pH 7.8],
150 mM NaCl, 1.5 mM MgCl2, 0.5% NP-40, 0.25% Triton X-100,
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10% glycerol) for 10 min at 4°C with rotation (12 rpm) before
being centrifuged at 1,200 rpm for 5 min at 4°C. The supernatant
was removed and the insoluble pellet was washed with wash
buffer (10 mM Tris–HCl [pH 8.0], 140 mM NaCl, 0.5 mM DTT) for
10 min at 4°C with rotation (12 rpm) before being centrifuged at
1,200 rpm for 5 min at 4°C. The supernatant was removed and the
insoluble pellet was resuspended in RIPA buffer (10 mM Tris–HCl
[pH 8.0], 140 mM NaCl, 0.1% sodium deoxycholate, 0.1% SDS,
1% Triton X-100) for 10 min at 4°C with rotation (12 rpm). Protein
concentration was then determined using the BCA assay (Thermo-
Fisher), and 20 lg of protein was analysed by SDS–PAGE. The
lambda phosphatase assay was performed on RIPA lysates contain-
ing 20 lg of protein and involved incubating the samples for
30 min at 4°C with ~400 U of lambda phosphatase (P0753L, NEB)
in 1x PMP (protein metallophosphatase) buffer containing 1 mM
MnCl2. Samples were heat denatured at 95°C for 3 min in 1×
Laemmli buffer and resolved on SDS–PAGE before Western blot
analysis. Nitrocellulose membranes were stained with Fast Green
(0.0001% w/v in 0.1% acetic acid) as a total protein stain and
imaged at 700 nm on the Odyssey infrared imaging system (LI-
COR Biosciences). Membranes were destained (0.1 M NaOH, 30%
methanol) for 10 min, washed with dH2O and then blocked (TBST,
5% milk) for 1 h, followed by sequential incubation with primary
and secondary antibodies. Signals were acquired using the Odyssey
infrared imaging system and analysed using Image Studio software,
except in Fig 5B, where signals were detected using chemilumines-
cence and the Fusion Solo imaging system. Primary antibodies
diluted in blocking buffer (TBST, 5% milk) included RPA2
(1:1,000, NA19L; Calbiochem), Histone H2A (1:1,000, 07-146;
Upstate), MRE11 (1:1,000, NB100-142; Novus), EXO1 (1:1,000,
A302-640A; Bethyl Laboratories), BRCA2 (1:2,000, A303-434A;
Bethyl Laboratories; 1:500, OP 95; EMD Millipore Ab-1), Histone
H3 (1:1,000, A300-823A; Bethyl Laboratories), CDC7 (1:1,000,
K0070-3; MBL), CHK1 (1:1,000, SC-8408; Santa Cruz Biotech) and
CDC45 (1:5, a gift from Broderick et al). Primary antibodies diluted
in blocking buffer (TBST, 1% BSA) included pS40/41 MCM2 (in-
house, 1:3,000), pS4/8 RPA32 (1:1,000, A300-254A; Bethyl Labora-
tories), pS139 H2AX (1:1,000; Cell Signaling Technology) and
pS345 CHK1 (1:1,000, 2348; Cell Signaling Technology). Secondary
antibodies (LI-COR Biosciences) were diluted in blocking buffer
(1:10,000, TBST, 5% milk) and included IRDye 800CW secondary
anti-rat (926–32,219), IRDye 800CW secondary anti-rabbit (926–
32,211) and IRDye 800CW secondary anti-mouse (926–32,210).
Flow cytometry
For flow cytometry analysis of cell cycle phases in combination with
pS139 histone H2AX, cells were treated as required followed by a
30 min pulse with EdU (10 lM) prior to harvest. Approximately
1 × 106 cells were processed by extraction of soluble proteins for
10 min on ice (PBS, 0.2% Triton X-100). Following centrifugation
(450 g, 5 min), cells were washed with PBS and fixed (PBS, 1%
PFA) at room temperature for 10 min and then incubated with
blocking buffer (PBS, 1% BSA). Cells were then sequentially incu-
bated in blocking buffer containing 0.05% saponin at room tempera-
ture with a primary antibody against pSer139 histone H2AX (1:500,
9718; Cell Signaling Technology) for 2 h, followed by washing, and
then with a secondary antibody (1:250, donkey a-rabbit Alexa Fluor
647, A32795; ThermoFisher) for 30 min in the dark. Incorporated
EdU was labelled with CLICK chemistry (10 lM 6-carboxyfluores-
cein-TEG-azide, 10 mM sodium L-ascorbate, 2 mM copper(II)
sulphate) for 30 min in the dark. Cells were washed (PBS, 1% BSA,
5% Tween-20) and DNA stained with DAPI (1 lg/ml, PBS, 1%
BSA). Data were acquired on a BD FACSCanto II and analysed using
FlowJo software.
Neutral comet assay
Cells were seeded at 3.5 × 105 cells/well in 60-mm plates and incu-
bated for 24 h. Following treatments, cells were harvested, counted
and diluted to 1 × 105 cells/ml with low melting agarose (LMA;
Trevigen) and spread across poly-lysine-coated slides. Slides with
LMA-embedded cells were incubated with lysis solution (Trevigen)
overnight, followed by electrophoresis at 4°C for 1 h with an applied
voltage of 1V/cm. DNA was stained with SYBR Green (1:10,000 in
10 mM Tris, pH 7.5, 1 mM EDTA) for 10 min at room temperature
in the dark. Fluorescence images were captured with a DeltaVision
Core wide-field microscope (GE Healthcare, Image solution) using a
10× UPlanFL N, N/A 0.30. Excitation and emission for FITC were
475 and 523 nm, respectively. Images were processed in ImageJ/Fiji
and analysed using CometScore software (version 2.0.0.38) to
measure comet tail moments. Statistical analysis was performed
using Prism 5 (GraphPad Software).
Chromosome spreads
Cells were seeded in 6-well plates at 1 × 105 cells/well, treated as
required and then washed three times with PBS, followed by addi-
tion of fresh media containing 200 ng/ml nocodazole for 16 h. Cells
were harvested and swollen with 75 mM KCl for 20 min at 37 °C
before being fixed with methanol:acetic acid (3:1). The fixing step
was repeated two times. Cells were then dropped onto pre-hydrated
glass slides and air-dried overnight before coverslips were mounted
onto the slides with Vectashield containing DAPI. Images of meta-
phase spreads were acquired with a 60× objective using an Olympus
IX51 microscope equipped with a Hamamatsu camera (C4742-95).
Images were processed using ImageJ/Fiji software [73], and visible
chromatid breaks were scored. Statistical analysis was performed
using Prism 5 (GraphPad Software).
Immunofluorescence
For PCNA/MRE11 colocalization studies, U2OS cells were seeded at
15,000 cells/well of Ibidi 8-well cell culture chamber l-slide and
allowed to recover for 24 h. Cells were treated as required, followed
by three washes with PBS, fixation with ice-cold methanol for
20 min, permeabilization with ice-cold acetone for 30 s and three
washes with PBS prior to blocking. For RAD51 or RPA/MRE11 colo-
calization studies, U2OS cells were seeded onto coverslips in 6-well
plates at 1 × 105 cells/well and treated as required. To detect
RAD51, cells were fixed, permeabilized and blocked as previously
reported [74]. For RPA/MRE11 colocalization, soluble proteins were
pre-extracted by incubation on ice for 10 min (CSK buffer: 10 mM
PIPES, pH 6.8, 10 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM
EGTA, 0.5% Triton X-100) before being washed with PBS. Cells
were then fixed (PBS, 4% PFA) for 20 min on ice and washed with
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PBS prior to blocking. For all immunofluorescence staining, cells
were blocked (PBS, 1% BSA) for 30 min and then incubated with
primary antibodies diluted in blocking buffer for 1 h at room
temperature. Cells were washed three times with PBS, followed by
incubation with secondary antibodies diluted in blocking buffer for
1 h at room temperature in combination with DAPI (0.5 lg/ml) to
stain nuclei. Cells were washed three times with PBS, and fluores-
cence images were captured with a DeltaVision wide-field micro-
scope (GE Healthcare, Image solution) using an oil 100X UPlanFL
N, N/A 1.30 objective. Excitations/emissions for DAPI, FITC and
TRICT were 390/435 nm, 475/523 nm and 542/594 nm, respec-
tively. Z-stacks composed of twelve slices with a 500-nm step were
acquired for each image. Following acquisition, image restoration
was applied and Huygens Professional (Scientific Volume Imaging)
was used to deconvolve images, using the Classic Maximum Likeli-
hood Estimation (CMLE) algorithm. Images were processed using
ImageJ/Fiji software, and the degree of colocalization between
proteins was analysed by measuring the Pearson correlation coeffi-
cient using ImageJ/Fiji [73]. Statistical analysis was performed
using Prism 5 (GraphPad Software). Primary antibodies included
RPA2 (1:500, NA19L; Calbiochem), Mre11 (1:500, NB100-142;
Novus), PCNA (1:1,000, SC-56; Santa Cruz) and RAD51 (1:1,000,
PC130; Calbiochem). Secondary antibodies included goat anti-rabbit
Alexa Fluor 488 (A11008; Molecular Probes; 1:500) and goat anti-
mouse Alexa Fluor 546 (A11003; Molecular Probes; 1:500).
DNA fibre analysis
Following depletion and/or inhibition of proteins of interest, cells
were sequentially pulse-labelled with halogenated nucleotides (CldU
and IdU) according to the treatment schemes displayed (Figs 4
and 5) and previously described protocols for preparation and anal-
ysis of DNA fibre spreads [25,50]. Briefly, cells were collected and
resuspended in PBS at 2.5 × 105 cells per ml. The labelled cells were
diluted 1:5 (v/v) with unlabelled cells, and 2.5 ll of cells was mixed
with 7.5 ll of lysis buffer (200 mM Tris–HCl, pH 7.5, 50 mM EDTA,
and 0.5% (w/v) SDS) on a glass slide. After 9 min, the slides were
tilted at 15–45°, and the resulting DNA spreads were air-dried and
fixed in 3:1 methanol/acetic acid overnight at 4°C. The fibres were
denatured with 2.5 M HCl for 1 h, washed with PBS and blocked
with 0.2% Tween-20 in 1% BSA/PBS for 40min. The newly repli-
cated CldU and IdU tracks were labelled (for 2.5 h in the dark, at
RT) with anti-BrdU antibodies recognizing CldU (1:500, ab6326;
Abcam) and IdU (1:100, B44, 347580; BD), followed by 1-h incuba-
tion with secondary antibodies at RT in the dark: anti-mouse Alexa
Fluor 488 (1:300, A11001; Invitrogen) and anti-rat Cy3 (1:150, 712-
166-153; Jackson ImmunoResearch Laboratories, Inc.). Fibres were
visualized (IX81; Olympus; objective lenses: LC Plan Fluor 60 × 1.42
NA oil Olympus BX60 microscope) and analysed using ImageJ soft-
ware. Statistical analysis was performed using Prism 5 (GraphPad
Software). Alternatively, DNA was combed and analysed as previ-
ously described by Eykelenboom et al (2013) (Fig 4C) [75]. Primary
antibodies included BrdU (BU1/75 (ICR1)) rat monoclonal antibody
(1:100, MA1-82088; ThermoFisher), anti-BrdU (B44) IgG1 mouse
monoclonal antibody (1:100, 347580; BD Biosciences) and anti-
ssDNA (poly dT) IgG2aj mouse monoclonal antibody (1:100,
mab3034; Sigma-Aldrich). Secondary antibodies included chicken
anti-rat Alexa Fluor 488 (1:300, A21470; ThermoFisher), goat anti-
mouse IgG1 Alexa Fluor 546 (1:300, A21123; ThermoFisher) and
goat anti-mouse IgG2a Alexa Fluor 647 (1:300, A21241; Thermo-
Fisher).
Electron microscopy analysis
The procedure was performed as recently described [50], with
minor modifications described below. Following the depletion of
the protein of interest, asynchronous sub-confluent cells were
treated with 4 mM HU for 5 h. Where indicated, cells were pre-
treated with XL413 for 30 min. Cells were collected, resuspended
in PBS and cross-linked with 4,50,8-trimethylpsoralen (10 lg ml-1
final concentration), followed by irradiation pulses with UV 365-
nm monochromatic light (UV Stratalinker 1800; Agilent Technolo-
gies). For DNA extraction, cells were lysed (1.28 M sucrose,
40 mM Tris–HCl (pH 7.5), 20 mM MgCl2 and 4% Triton X-100;
Qiagen) and digested (800 mM guanidine-HCl, 30 mM Tris–HCl
(pH 8.0), 30 mM EDTA (pH 8.0), 5% Tween-20 and 0.5% Triton
X-100) at 50°C for 2 h in the presence of 1 mg/ml proteinase K.
The DNA was purified using chloroform/isoamyl alcohol (24:1)
and precipitated in 0.7 volume of isopropanol. Finally, the DNA
was washed with 70% EtOH and resuspended in 200 ll TE (Tris–
EDTA) buffer. Restriction enzyme of 100 U (PvuII high fidelity;
New England Biolabs) was used to digest 12 lg of mammalian
genomic DNA for 4–5 h. Replication intermediate enrichment was
performed by QIAGEN Plasmid Mini Kit columns. The QIAGEN-tip
20 surface tension was reduced by applying 1 ml QBT buffer. The
columns were washed and equilibrated with 10 mM Tris–HCl (pH
8.0) and 1M NaCl, followed by 10 mM Tris–HCl (pH 8.0) and
300 mM NaCl, respectively. DNA was then loaded onto the
columns. The columns were then washed with high-NaCl solution
(10 mM Tris–HCl (pH 8.0) and 900 mM NaCl) and eluted in caf-
feine solution (10 mM Tris–HCl (pH 8.0), 1M NaCl and 1.8%
(w/v) caffeine). To purify and concentrate the DNA, an Amicon
size-exclusion column was used. DNA was then resuspended in TE
buffer. The benzyldimethylalkylammonium chloride method was
used to spread the DNA on the water surface and then load it on
carbon-coated 400-mesh copper grids. Subsequently, DNA was
coated with platinum using a high-vacuum evaporator (MED 020;
BalTec). Microscopy was performed with a transmission electron
microscope (Tecnai G2 Spirit; FEI; LaB6 filament; high tension
≤ 120 kV) and picture acquisition with a side-mount charge-
coupled device camera (2,600 × 4,000 pixels; Orius 1000; Gatan,
Inc.). For each experimental condition, at least 70 replication fork
molecules were analysed. DigitalMicrograph version 1.83.842
(Gatan, Inc.) and ImageJ (National Institutes of Health) were used
to process and analyse the images. Statistical analysis was
performed using Prism 5 (GraphPad Software).
Expanded View for this article is available online.
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